TRPML modulator

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
Compounds targeting TRPML1 are developed to enhance autophagy, addressing the lack of effective modulation in current methods and offering therapeutic benefits for neurodegenerative disorders, cancer, and heart disease.

JP7917440B2Active Publication Date: 2026-09-08CASMA THERAPEUTICS INC

13 Cites 0 Cited by

Patent Information

Application Number: JP2022538202
Authority / Receiving Office: JP · JP
Patent Type: Patents
Current Assignee / Owner
Priority Date: 2020-12-01
Filing Date: 2020-12-18
Publication Date: 2026-09-08
Estimated Expiration: 2040-12-18

Application Information

Patent Timeline

01 Dec 2020

Priority

18 Dec 2020

Application

JP2022538202

08 Sep 2026

Publication

JP7917440B2

IPC: C07D211/32; C07D401/06; C07D413/06; C07D295/135; A61P43/00; A61P3/00; A61P25/00; A61P25/28; A61P25/14; A61P25/16; A61P21/00; A61P31/00; A61P31/06; A61P31/04; A61P1/16; A61P1/04; A61P29/00; A61P35/00; A61P9/10; A61K31/496; A61K31/495; A61K31/451; A61K31/18; A61K31/4995; A61K31/4439; A61K31/454; A61K31/5377; A61K31/397; A61K31/407; A61K31/675; A61K31/444; A61K31/402; A61K31/46; A61K31/501; A61K31/497; A61K31/438; A61K31/662; A61K31/5375; A61K31/404; A61K31/5386; A61K31/4025; A61K31/4525; A61K31/453; A61K31/551; A61K31/437; A61K31/4535; A61K31/4523; A61K31/4545; A61K31/55; A61K31/4418

CPC: C07D295/096; C07D241/04; C07D405/06; C07D211/22; C07D401/14; C07D451/00; C07D333/52; C07D401/12

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Antibacterial agents Nervous disorder

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

Current methods do not effectively modulate TRPML1 to enhance autophagy, which is beneficial for treating various diseases and disorders such as neurodegenerative disorders, cancer, and heart disease.

Method used

Development of specific compounds that modulate TRPML1, specifically as agonists, to enhance autophagy and treat related diseases and disorders.

Benefits of technology

Enhances autophagy, providing therapeutic benefits for neurodegenerative disorders, cancer, and heart disease by targeting TRPML1 with modulating compounds.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using them.

Need to check novelty before this filing date? Find Prior Art